Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Oxford Structural Genomics Consortium (SGC) is a key member of a new EUbOPEN consortium which has been awarded funding from the Innovative Medicines Initiative to develop openly available chemical tools for understanding human biology.

None

The Oxford Structural Genomics Consortium (SGC) is a key member of a new consortium, “Enabling and Unlocking biology in the Open” (EUbOPEN), which has been awarded an Innovative Medicines Initiative grant worth over 66 million Euros. The project will last five years.

The EUbOPEN project builds on the efforts of the successful ULTRA-DD consortium previously led by the University of Oxford, and will be led by Goethe University Frankfurt, and the pharmaceutical company Boehringer Ingelheim. The consortium consists of 22 partners from academia and industry that will work together to develop high quality chemical tools that can be used to investigate the biology of disease and discover new targets for drug discovery. In keeping with the SGC commitment to open science, the project outputs will be made openly available to the research community, without restriction, including chemogenomic library sets, chemical probes, assay protocols and associated research data.

The research at the University of Oxford will be directed by Professor Chas Bountra, the Chief Scientific Officer of SGC Oxford and the University of Oxford’s Pro Vice-chancellor for innovation, and Dr Jon Elkins, Principal Investigator at SGC Oxford.

Read more on the EUbOPEN website

Similar stories

Oxford University wins prestigious Queen’s Anniversary Prize

Her Majesty The Queen has approved the award of The Queen’s Anniversary Prizes to twenty-one higher and further education institutions, including Oxford University, in the most recent round of the independently reviewed scheme. This prestigious award is the highest national honour available to universities and FE colleges across the UK.

Jenner Institute named Covid Innovation Heroes

The team at the University of Oxford’s Jenner Institute has been celebrated for their global pandemic work by The Oxford Trust’s Covid Innovation Heroes Award­ 2021.

New Research Highlights Importance of Early Years Development on Future Wellbeing

Oxford researchers involved nearly 4,000 children across the UK in three specially developed science lessons to educate pupils about brain development during early childhood. The SEEN (Secondary Education around Early Neurodevelopment) project was commissioned and funded by KindredSquared and is part of a wider drive to increase public understanding of how early experiences can shape the adults we become.

Study reveals ‘stop-eating’ response to DNA damage

A new study from the MRC Weatherall Institute of Molecular Medicine sheds light on the mechanism by which DNA damage suppresses appetite, a finding with implications for understanding the appetite lowering side-effects of chemotherapy.

Fiona Powrie appointed new Deputy Chair of Wellcome’s Board of Governors

Fiona Powrie, Director of the Kennedy Institute of Rheumatology at the University of Oxford has been selected as the next Deputy Chair of Wellcome’s Board of Governors.